Press release from Companies
Publicerat: 2025-05-30 08:45:00
SensoDetect AB (publ) announces continued and steady progress in its clinical study aimed at the early detection of autism spectrum disorder (ASD). With 55 assessments now completed, the company is preparing to launch the planned interim analysis—a significant milestone in its product development and commercialization roadmap.
“This milestone enables us to derive valuable insights into data trends and evaluate the integrity of our collection protocols,” says Dr. Saleh AlSalehi, MD, Lead Principal Investigator and CBAHI Hospital Surveyor, Saudi Arabia. “The interim analysis will play a pivotal role as we scale our technology for broader autism screening—ultimately targeting early detection across all pediatric age groups, with a long-term goal of enabling screening within the first 24 hours of life.”
SensoDetect’s proprietary platform, SensoDetect BERA, is a CE-marked, non-invasive diagnostic solution that analyzes brainstem auditory responses to identify neurological patterns associated with autism and other neurodevelopmental conditions. Designed for practical use in a variety of clinical settings, the platform delivers objective results without requiring verbal input from the patient—making it ideal for both children and non-communicative individuals.
“We are entering a decisive phase in our roadmap,” says PA Hedin, CEO of SensoDetect AB. “This interim analysis is not just a research milestone—it is a strategic lever that accelerates our journey toward regulatory alignment, clinical validation, and commercial success. It strengthens our commitment to creating long-term shareholder value while meeting a global healthcare need.”
Strategic Importance for Shareholders
The global autism diagnostics market is expanding rapidly, driven by increased awareness and demand for early, objective assessments. SensoDetect is well-positioned at the forefront of this evolution, offering a scalable, medically certified technology suitable from infancy through adulthood. With growing clinical interest and early-stage engagement from international partners, the company anticipates that results from the interim analysis will further solidify its competitive position and support future activities in licensing, regulatory approval, and market expansion.
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
pa.hedin@sensodetect.com
SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of diagnostics, medication, and health. The products are used in both private and public healthcare as a complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.
More info at https://www.sensodetect.com/
